Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ARTL
stocks logo

ARTL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-1.570
-77.64%
--
--
-0.260
-93.98%
--
--
-0.240
-95.72%
Estimates Revision
The market is revising No Change the revenue expectations for Artelo Biosciences, Inc. (ARTL) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -54.32%.
EPS Estimates for FY2025
Revise Upward
up Image
+66.12%
In Past 3 Month
Stock Price
Go Down
down Image
-54.32%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Artelo Biosciences Inc (ARTL.O) is -0.38, compared to its 5-year average forward P/E of -4.40. For a more detailed relative valuation and DCF analysis to assess Artelo Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.40
Current PE
-0.38
Overvalued PE
6.28
Undervalued PE
-15.07

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.26
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.34
Undervalued EV/EBITDA
-0.86

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ARTL News & Events

Events Timeline

(ET)
2025-12-03
08:40:00
Artelo Biosciences Publishes New Study Showing SBFI103 Reduces Anxiety and Depression
select
2025-11-12 (ET)
2025-11-12
08:02:02
Artelo Biosciences Announces Q3 Earnings Per Share of $3.97 Compared to $2.10 in the Previous Year
select
2025-11-04 (ET)
2025-11-04
08:33:27
Artelo Biosciences releases peer-reviewed study on fatty acid binding proteins
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-19Benzinga
Maxim Group Lowers Artelo Biosciences Rating to Hold

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, fostering a collaborative environment for sharing market intelligence.

  • Market Success: Traders utilize Benzinga Pro's resources to gain a competitive edge and improve their chances of winning in the markets daily.

[object Object]
Preview
9.0
09-30Benzinga
Wolfspeed Shares Surge Over 50%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Wolfspeed's Reorganization: Wolfspeed, Inc. announced a court-approved reorganization plan that will reduce its debt by 70% and interest payments by 60%, leading to a 50.9% increase in its stock price during pre-market trading.

  • Other Notable Stock Movements: Several companies saw significant pre-market trading gains, including Sunrise New Energy Co. (up 97%) and Vivakor, Inc. (up 67%), while others like Epsium Enterprise Limited and Artelo Biosciences, Inc. experienced notable declines.

[object Object]
Preview
8.5
09-30SeekingAlpha
Artelo Biosciences Initiates Underwritten Public Offering to Secure Funding

  • Public Offering Announcement: Artelo Biosciences has initiated an underwritten public offering of its common stock and/or pre-funded warrants, with all shares being offered by the company.

  • Market Conditions Impact: The completion, final size, and terms of the offering are contingent on market conditions, and there is no assurance regarding the timing or completion of the offering.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Artelo Biosciences Inc (ARTL) stock price today?

The current price of ARTL is 2.06 USD — it has increased 24.85 % in the last trading day.

arrow icon

What is Artelo Biosciences Inc (ARTL)'s business?

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.

arrow icon

What is the price predicton of ARTL Stock?

Wall Street analysts forecast ARTL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARTL is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Artelo Biosciences Inc (ARTL)'s revenue for the last quarter?

Artelo Biosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Artelo Biosciences Inc (ARTL)'s earnings per share (EPS) for the last quarter?

Artelo Biosciences Inc. EPS for the last quarter amounts to -3.96 USD, increased 88.57 % YoY.

arrow icon

What changes have occurred in the market's expectations for Artelo Biosciences Inc (ARTL)'s fundamentals?

The market is revising No Change the revenue expectations for Artelo Biosciences, Inc. (ARTL) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -54.32%.
arrow icon

How many employees does Artelo Biosciences Inc (ARTL). have?

Artelo Biosciences Inc (ARTL) has 6 emplpoyees as of December 05 2025.

arrow icon

What is Artelo Biosciences Inc (ARTL) market cap?

Today ARTL has the market capitalization of 4.10M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free